(Q46273820)

21 December 2017

title

Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors (English)

1 reference

21 December 2017

author

Johannes-Peter Stasch

19

object named as

Johannes-Peter Stasch

1 reference

21 December 2017

Hartmut Schirok

1

1 reference

21 December 2017

Raimund Kast

2

1 reference

21 December 2017

Santiago Figueroa-Pérez

3

1 reference

21 December 2017

Samir Bennabi

4

1 reference

21 December 2017

Mark J Gnoth

5

1 reference

21 December 2017

Achim Feurer

6

1 reference

21 December 2017

Heike Heckroth

7

1 reference

21 December 2017

Michael Thutewohl

8

1 reference

21 December 2017

Holger Paulsen

9

1 reference

21 December 2017

Andreas Knorr

10

1 reference

21 December 2017

Joachim Hütter

11

1 reference

21 December 2017

Mario Lobell

12

1 reference

21 December 2017

Klaus Münter

13

1 reference

21 December 2017

Volker Geiss

14

1 reference

21 December 2017

Heimo Ehmke

15

1 reference

21 December 2017

Dieter Lang

16

1 reference

21 December 2017

Martin Radtke

17

1 reference

21 December 2017

Joachim Mittendorf

18

1 reference

21 December 2017

publication date

1 December 2008

1 reference

21 December 2017

published in

ChemMedChem

1 reference

21 December 2017

volume

3

1 reference

21 December 2017

issue

12

1 reference

21 December 2017

page(s)

1893-1904

1 reference

21 December 2017

Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

ZIP kinase, a key regulator of myosin protein phosphatase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho activation at a glance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rocks: multifunctional kinases in cell behaviour

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinases in cardiovascular physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho GTPases in animal cell mitosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Involvement of Rho kinase in endothelial barrier maintenance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho/ROCK pathway as a target of tumor therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinase in the regulation of cell death and survival

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinase, a promising drug target for neurological disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho-ROCK inhibitors for the treatment of CNS injury.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

A ROCK inhibitor permits survival of dissociated human embryonic stem cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho-kinase is an important therapeutic target in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Targeting Rho and Rho-kinase in the treatment of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Physiological role of ROCKs in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinase (ROCK) inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Development of Rho-kinase inhibitors for cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Applications for ROCK kinase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Development of specific Rho-kinase inhibitors and their clinical application

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

The structure of dimeric ROCK I reveals the mechanism for ligand selectivity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

The selectivity of protein kinase inhibitors: a further update

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl)cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Design and synthesis of Rho kinase inhibitors (I).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Design and synthesis of rho kinase inhibitors (III).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Design and synthesis of Rho kinase inhibitors (II).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

A method for measuring Rho kinase activity in tissues and cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Detection of myosin light chain phosphorylation--a cell-based assay for screening Rho-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle contraction via myosin light chain phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

ZIP kinase is responsible for the phosphorylation of myosin II and necessary for cell motility in mammalian fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Synthesis of 4-amino-1-beta-D-ribofuranosyl-1H-pyrrolo[2,3-b]pyridine (1-deazatubercidin) as a potential antitumor agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800211

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800211

1 reference

21 December 2017

1 reference

21 December 2017